10X Genomics Reaches New 52-Week High of $37.49, Up 67.49%

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 37.49 on June 29, 2026. This achievement marks a remarkable 67.49% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 20.53% during the same period. With a market capitalization of USD 2,489 million, 10X Genomics operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics reveal a price-to-book ratio of 3.13, indicating its valuation relative to its net assets. However, it is important to note that the company is currently loss-making, as reflected by its negative price-to-earnings ratio and return on equity of -10.80%. Additionally, the company maintains a debt-to-equity ratio of -0.64, suggesting a unique financial structure. As 10X Genomics continues to navigate the dynamic landscape of biotechnology, its recent stock performance underscores its position within the market.